Background Tumour necrosis factor-alpha (TNFa) has been found to be very effective in the isolated limb perfusion setting for advanced extremity tumours. In a phase I study of intrapleural administration of TNFa 5 patients were followed for inflammatory response patterns.
Introduction
Malignant mesothelioma is a tumour associated with exposure to asbestos [1] . Recent studies have indicated that the incidence of malignant mesothelioma with its long time between exposure and presentation of the disease will continue to rise in the future [2] .
Malignant mesothelioma is a notoriously refractory tumour to all current treatments. Neither surgery [3] nor radiotherapy [4, 5] results in an increased survival. The median survival of mesothelioma is about 10 months [4, 6, 7] . Therefore various alternative approaches have been tested [8] . Pleural mesothelioma tends to stay locoregionally throughout most of its natural course [9] . This biological behaviour makes this disease amenable to locoregional administration of cytostatic agents or biologic agents such as interferon-gamma (IFNg) [10] , interferonalpha [11] , IL-2 [12] [13] [14] . With intrapleural administration of IFNg or IL-2 antitumour responses have been recorded and it was speculated that TNFa might be implicated in these antitumour effects. Thus we decided to explore intrapleural administration of TNFa, a cytokine that had failed systemic administration because of excessive toxicity [15, 16] . Therefore the clinical use of TNFa is restricted to locoregional application. It is already very successfully used in the treatment of irresectable sarcoma and melanoma [17, 18] .
There are very few reports on intracavitary TNFa in humans. TNF has been administered intraperitoneally in patients with advanced peritoneal carcinomatosis [19, 20] . Regional toxicity (abdominal pain) instead of systemic toxicity was the dose-limiting factor in this setting. Intrapleural administration was studied in patients with malignant pleural effusion by Karck et al. [21] . Treatment with up to 200 mg/m 2 weekly, led in 3 out of 6 patients to disappearance of effusion. Because of this preclinical and clinical data, we decided to perform a phase I study in patients with stage I-IIA malignant pleural mesothelioma with rTNFa to study the clinical effect on pleural mesothelioma and evaluate the inflammatory response after this mode of administration.
We have previously shown [22] that leakage of TNFa during isolated limb perfusion (ILP) caused an acute-phase response. This was demonstrated by an increase of IL-6 directly after ILP until 2 days thereafter, followed by increase of CRP, a1-AG and a1-antitrypsin after 1 day, and decrease of negative acute-phase proteins albumin and transferrin during ILP till 6 h after ILP.
In the literature it is questioned whether the acute-phase protein response (APR) could be down regulated by a repeated stimulus [23] . Clinical studies have shown that in a number of chronic inflammatory diseases the APR is less than would be expected for the activity of inflammation [24] [25] [26] . In our patients a repeated stimulus is mimicked: at regular time intervals, 2 weeks, TNFa is administered. This enables us to investigate whether repeated administration of TNFa is still able to provoke an acute-phase response.
Patients and methods

Patients
Five patients with pleural mesothelioma in a phase I study were, respectively, sampled for evaluation of biologic response patterns. Demographical and clinical characteristics are summarised in Table 1 . Staging and diagnosis of mesothelioma was based on computerised tomographic (CT) scan of the chest, thoracoscopic findings and histological examination of biopsy samples. According to Butchart's staging system [27] stage I is defined as tumour confined within the capsule of the parietal pleura, i.e. involving only ipsilateral pleura, lung, diaphragm and external surface of the pericardium within pleural reflection. Stage IIA is defined as mesothelioma invading chest wall or mediastinal tissues with or without lymphnode involvement ipsilaterally inside the chest.
Eligibility criteria required histologically confirmed pleural mesothelioma stage I-IIA, sufficient pleural effusion to insert an intrapleural catheter, no signs of loculation on the CT scan, no prior chemo-, radio-or immunotherapy, age < 76 years, Karnofsky performance status Ն 80%, no cardiovascular disease, a white blood cell count Ն 4·0 × 10 9 l
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, platelets Ն 100 × 10 9 l ¹1 , serum bilirubin and creatinine levels within the institution's normal range, no active infection, no use of corticosteroids and obtained informed consent. The protocol was approved by the hospital's ethical committee. 
Treatment schedule
About 2 weeks before the first administration of TNFa a Port-a-cath system was surgically inserted under general anaesthesia. The correct intrapleural position was examined radiographically and a technetium-99 m colloid scan was made to evaluate the distribution of pleural fluid throughout the pleural cavity. Recombinant human TNFa (Boehringer Ingelheim, Germany) was administered as an intrapleural infusion, repeated every 14 days. Four patients were treated with a dose of 0·1 mg, one patient with 0·2 mg.
Tumour response evaluation
Response was evaluated after every 6 cycles using CT scan of the chest. Tumour response and toxicity were assessed according to the criteria of the World Health Organisation (1979) [28] . In case of measurable disease, complete response (CR) was defined as the disappearance of all known disease for at least 4 weeks; partial response (PR) as a decrease of > 50% in tumour size for at least 4 weeks; stable disease (SD) as a decrease of < 50% in tumour size. Progressive disease (PD) was defined as an increase of > 25% in the diameter of any lesion or the appearance of a new lesion.
Immunomonitoring and cytokine-and acute-phase protein assays
Both serum samples and pleural fluid were collected at 4 time-points during each cycle: 24 h before administration of TNFa, 24 h and 48 h after administration and at day 8. All samples were cryopreserved until testing.
Levels of TNFa, IL-6, IL-8, CRP and sPLA 2 were measured using enzyme-linked immunosorbent assays (ELISA). Used antibodies were obtained from the Central Laboratory of the Blood Transfusion Service (Amsterdam, the Netherlands).
For measuring TNFa, as described previously [29] , flatbottomed microtitre plates (Nunc, Kamstrup, Denmark) were coated overnight with purified monoclonal antibody (MAb) against TNFa (CLB-TNF/7). After washing serial dilutions of TNF-containing samples were added. Bound TNFa was detected by biotinylated sheep anti-TNFa. The detection limit of the assay was 5 pg mL
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. Healthy controls were below 5 pg mL
. The IL-6 specific ELISA was described previously [30] . A coat of CLB-IL-6/16 was applied overnight and bound IL-6 was detected by biotinylated affinity-purified polyclonal sheep anti-IL-6. Lower detection limit was 1 pg mL ¹1 and normal healthy control subjects were below 10 pg mL ¹1 . For IL-8 [31] a coat of CLB-IL-8/1 MAb was applied overnight and bound IL-8 was detected by biotinylated affinity-purified polyclonal sheep anti-IL-8. The lower detection limit of this assay was 8 pg mL ¹1 . Normal values were below 20 pg mL ¹1 .
CRP levels were measured by a sandwich ELISA using polyclonal rabbit antihuman CRP Abs as catching Abs and biotinylated MAb anti-CRP (CLB anti-CRP-2) as a detecting Ab [32] . Results were referred to a standard (Behringwerke AG, Marburg, Germany) and expressed in mg L ¹1 . Detection limit was 10 ng L ¹1 . The ELISA used for measuring sPLA 2 was described before [33] . Two different monoclonal antibodies against human sPLA 2 were used as coating and catching antibodies, respectively. The lower limit of detection was 0·1 ng mL ¹1 . Normal healthy volunteers were below 5 ng mL
. Levels of a1-acid glycoprotein were measured by means of a nephelometric assay. Antisera were obtained from the Central Laboratory of the Blood Transfusion Service (Amsterdam, the Netherlands). Normal values were 400-900 mg L ¹1 .
Results
Cytokine and acute-phase protein levels in pleural fluid
Peak-levels (median with range) of cytokines and acutephase proteins of all patients are represented in Table 2 . In Figure 1 measurements of the first 6 cycles of patient 2 are depicted, the results of the other patients were comparable. After TNF-administration the concentration of TNFa increased in 24 h to levels in the range of 50-100 ng mL ¹1 . After 48 h still some TNFa was measurable (150-500 pg mL ¹1 ). No TNFa was measurable after 8 and 14 days. Before the first administration of TNFa IL-6 was increased in all patients, values varying from 1200 to 80 000 pg mL
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. It rose sharply to 100 ng mL ¹1 after 24 h and 250 ng mL ¹1 after 48 h. After 8 days it declined to 30-80 ng mL ¹1 , after 14 days levels were in the range of 15-33 ng mL ¹1 . IL-8 started at 180-260 pg mL ¹1 . It increased sharply during in the first 24 h to 2-12 ng mL ¹1 , then it decreased to 0·7-1·0 ng mL ¹1 at 48 h and about 200 pg mL ¹1 after 8 days. After 14 days levels were around 150 pg mL ¹1 . Levels of CRP increased during the first cycle from 3 mg L ¹1 at start to 60 mg L ¹1 after 8 days. Thereafter values remained constant around 60 mg L ¹1 . sPLA 2 increased during 48 h from around 5 ng mL ¹1 (3-9 ng mL ¹1 after 24 h) to 20-30 ng mL ¹1 . It decreased slowly over the following 2 weeks. Levels of a1-AG remained constant around 1300 mg L ¹1 after a slow rise from 700 mg L
. The production of cytokines demonstrated the same pattern even after cycle 12 in patient 2.
Serum-cytokine and acute-phase protein levels
In serum (Fig. 2, Table 2 ) no TNFa and no IL-8 was measurable in any patient. IL-6 could not be detected in 2 patients but rose sharply in the other 3, 24 h after TNF-administration; values were in the range of 125-275 pg mL
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. At 48 h it was still measurable in the first 4 cycles. In the course of treatment IL-6 levels gradually decreased. Before the first administration of TNFa, CRPlevels in serum were increased in all patients (31-300 mg L
). CRP-levels increased slowly from around 100 mg L ¹1 after 24 h to 500 mg L ¹1 after 48 h. 
Toxicity and tumour response
Five male patients were treated with intrapleural infusion of TNFa. Stage I patients were treated with 0·1 mg and one patient with stage IIA mesothelioma was treated with 0·2 mg. One patient received only one dose of TNFa: Because of excessive pleural effusion, for which the patient needed drainage of pleural fluid, complicated by a haematothorax, further intrapleural TNF-administration could not be pursued. The other 4 patients were evaluable for toxicity and tumour response as they received a minimum of 6 doses up to 18 doses. Overall tolerance was quite good. All patients developed flu-like symptoms and mild fever (38-39·3 ЊC) during 1-2 days. Two patients had a short episode of nausea and vomiting. No grade III-IV toxicity according to the WHO-criteria [28] was observed.
No hypotension or increase in heart rate was observed. Furthermore, intrapleural TNFa had no effect on number of leukocytes and thrombocytes, kreatinin and liver functions. None of the patients had a tumour response, only one patient showed stable disease during 36 weeks. Of note, once started with treatment none of the patients needed drainage of pleural fluid any more. In 2 patients dyspnea diminished obviously during treatment. Concerning the other 2 patients: in one patient dyspnea did not change and one patient did not have complaints of breathlessness. no peak 2100-2540 no peak 740-1620 *Only 1 cycle. †IL-6 was measurable only during the first two cycles, thereafter it was under detection limit ND: not measured.
Discussion
In the present study the biologic effects of intrapleural administration of TNFa in patients with pleural mesothelioma was studied. The results of the cytokine measurements before administration of TNFa showed signs of an ongoing inflammatory response. This was also observed by others [34, 35] . Before administration of TNFa intrapleural levels of IL-6, IL-8, CRP, sPLA 2 and a1-AG were elevated. In serum we found increased levels of CRP and a1-AG. Our measurements correspond to the observations of Nakano et al. and Monti et al. The high intrapleural IL-6 levels, before the first administration of TNFa, appeared to be caused by production by the mesothelioma-cells. IL-6 has been shown to be produced by mesothelioma-cells in vitro [36, 37] . IL-6, produced in the pleural cavity, leaking to the systemic circulation, is thought to be the responsible cytokine for the induction of the acute-phase response. The mechanism of the acutephase response has been investigated and described earlier, both in vitro [38, 39] and in vivo [26, 40, 41] . Intrapleural administration of TNFa resulted in clear IL-6, CRP, sPLA 2 and a1-AG patterns in serum, with the noticeable exception for TNFa and IL-8, which never reached detectable levels systemically. This may be explained by soluble receptors for TNFa and IL-8. With respect to the IL-6 response in serum a significant increase with a peak after 48 h was observed after each TNFadministration. However the response diminished gradually in the course of time, most illustrative visible in patient 2 in which no detectable IL-6 levels were observed when TNFa had been administered more than 9 times. This points to an 'exhaustion' phenomenon or a gradual build-up of soluble IL-6 receptor levels. However, the acute-phase response was not diminished. This may be explained by a direct stimulation of the acutephase response by TNFa and IL-1 [26, 40] . TNFa and IL-1 are only able to stimulate the positive acute-phase proteins. So in our study (we only determined positive acute-phase proteins) we could not distinguish which cytokine had the most impact on the stimulation of the APR: IL-6 or TNFa/IL-1. In contrast with the studies mentioned above [24] [25] [26] , we could not find a down-regulation of the APR, even though the acute-phase response was already activated before the first TNF-administration. Administration of TNFa did increase the levels of the acute-phase proteins; this indicates that the APR was not maximally stimulated before the first TNF-administration. A possible explanation for the fact that we did not find a downregulation of the APR could be the relatively long treatment free period of 2 weeks between the consecutive administrations of TNFa.
TNFa had no antitumour effect in these 4 mesotheliomapatients, but seemed to diminish pleural effusion. Reduction of pleural fluid was also described before [21, 42] . The mechanism why TNF reduces pleural fluid is not quite clear. Most likely, fluid production by mesothelioma cells is reduced. Enhanced resorption of pleural fluid is less likely as this mechanism would be associated with higher systemic levels of TNFa and other cytokines, which we did not observe.
In conclusion, intrapleural administration of TNFa was followed by a clear inflammatory response locoregionally. In spite of TNFa peak levels as high as 700 ng mL ¹1 systemic levels were never detectable. The secondary cytokine response led to very high intrapleural IL-6 and IL-8 levels. Systemically IL-8 levels were never detectable whereas high IL-6 levels were induced systemically initially, with a decreased response to each intrapleural TNFa administration over time. The acute-phase response in contrast remained remarkably constant throughout the course of repetitive intrapleural administrations of TNFa. Intrapleural administration of TNFa is well tolerated but associated with a rather moderate impact on production of TNF alpha pg mL pleural fluid. As this effect can be achieved by other simpler and cheaper treatment we see no justification for further studies.
